Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
NCT05873686 · View on ClinicalTrials.gov ↗
Study Summary
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Conditions Studied
Interventions
- DRUG NXP900
Study Locations (12)
Texas
- The University of Texas MD Anderson Cancer Center — Houston
- NEXT Oncology Houston — Houston
- NEXT Oncology Dallas — Irving
Other
- Western General Hospital - NHS Lothian — Edinburgh
- The Royal Marsden NHS Foundation and Trust — London
Arizona
- Mayo Clinic — Phoenix
Colorado
- Sarah Cannon Research Institute at HealthONE — Denver
Florida
- Mayo Clinic — Jacksonville
Illinois
- University of Chicago — Chicago
Minnesota
- Mayo Clinic Rochester — Rochester
Oregon
- Oregon Health and Science University — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-10-26 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05873686
The ClinicalTrials.gov registry entry for NCT05873686 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvectis Pharma, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention — of which NXP900 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05873686 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Texas, Other, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05873686 about?
NCT05873686 is a clinical study titled "A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers". This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterat...
What is the current status of trial NCT05873686?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-10-26. Estimated completion is 2027-07.
What conditions does trial NCT05873686 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Mesothelioma, Renal Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Squamous Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05873686?
The interventions under investigation include: NXP900 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05873686?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05873686 being conducted?
This trial has 12 study locations across Arizona, Colorado, Florida, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.